Eton Pharmaceuticals, Inc.
ETON
$16.90
-$2.24-11.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.32M | 58.18M | 48.33M | 39.01M | 34.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.32M | 58.18M | 48.33M | 39.01M | 34.68M |
| Cost of Revenue | 31.67M | 22.41M | 20.06M | 15.60M | 14.11M |
| Gross Profit | 38.65M | 35.77M | 28.27M | 23.41M | 20.57M |
| SG&A Expenses | 33.27M | 30.45M | 26.35M | 22.34M | 20.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.05M | 57.37M | 50.18M | 41.19M | 39.90M |
| Operating Income | 267.00K | 815.00K | -1.85M | -2.18M | -5.22M |
| Income Before Tax | -6.48M | -4.03M | -4.50M | -3.81M | -5.31M |
| Income Tax Expenses | 199.00K | 101.00K | 89.00K | 15.00K | 175.00K |
| Earnings from Continuing Operations | -6.68 | -4.13 | -4.58 | -3.82 | -5.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.68M | -4.13M | -4.58M | -3.82M | -5.48M |
| EBIT | 267.00K | 815.00K | -1.85M | -2.18M | -5.22M |
| EBITDA | 3.58M | 3.40M | 3.00K | -1.11M | -4.17M |
| EPS Basic | -0.25 | -0.15 | -0.18 | -0.15 | -0.21 |
| Normalized Basic EPS | -0.08 | -0.06 | -0.10 | -0.08 | -0.13 |
| EPS Diluted | -0.26 | -0.17 | -0.19 | -0.16 | -0.22 |
| Normalized Diluted EPS | -0.08 | -0.06 | -0.10 | -0.08 | -0.13 |
| Average Basic Shares Outstanding | 106.81M | 105.82M | 104.70M | 103.58M | 103.18M |
| Average Diluted Shares Outstanding | 106.81M | 106.47M | 105.35M | 104.23M | 103.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |